The International Genomics Consortium
- Assets
- $13.9m
- Revenue
- $3.4m
- Investments
- $0.0
- Employees
- 0
- Location
- Phoenix, AZ
- Founding
- 02/2002
- Data as of
- 12/2021
- EIN
- 86-1024333
Organization Overview
The International Genomics Consortium is located in Phoenix, AZ. The organization was established in 2002. According to its NTEE Classification (H30) the organization is classified as: Cancer Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. International Genomics Consortium is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, International Genomics Consortium generated $3.4m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 7 years, the organization has seen revenues fall by an average of (4.3%) each year. All expenses for the organization totaled $2.0m during the year ending 12/2021. As we would expect to see with falling revenues, expenses have declined by (12.6%) per year over the past 7 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
WORK TO REVOLUTIONIZE THE TREATMENT AND PREVENTION OF CANCER AND COMPLEX DISEASES.
Describe the Organization's Program Activity:
Part 3 - Line 4a
ISPECIMEN - ISPECIMEN ADDRESSES A CRITICAL CHALLENGE CONNECTING LIFE SCIENCE RESEARCHERS WHO NEED HUMAN BIOSPECIMENS WITH THE BILLIONS OF SPECIMENS AVAILABLE IN HEALTHCARE ORGANIZATIONS WORLDWIDE. ISPECIMEN'S GROUND-BREAKING MARKETPLACE SOLVES THIS PROBLEM, REINVENTING THE BIOSPECIMEN PROCUREMENT PROCESS TO ACCELERATE MEDICAL RECOVERY.PARADIGM DIAGNOSTICS - PARADIGM'S RESEARCH BRINGS CUTTING EDGE DIAGNOSTICS AND BIOMARKER DRIVEN CLINICAL TRIALS TO THE BENEFIT OF CANCER PATIENTS. PARADIGM ATTEMPTS TO DEVELOP POTENTIAL THERAPIES BASED ON SPECIFIC CHARACTERIZATION OF THE PATIENT'S TUMOR, PERSONALIZING EACH PATIENT'S COURSE OF TREATMENT.
VIOMICS - DIAGNOSTIC AND BIOMARKER RESEARCH WITH A FOCUS ON LUNG CANCER.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
David Mallery President & CEO | OfficerTrustee | 20 | $240,000 |
Scott Morris Chief Scientific Officer | Officer | 20 | $120,000 |
Troy Shelton Board Member, VP Of Operations | Trustee | 20 | $47,750 |
Vanesa Romero CFO | Officer | 16 | $36,000 |
Robert Armknecht Jr Board Member | Trustee | 0.5 | $20,000 |
Erin Curley Board Member | OfficerTrustee | 0.5 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Scott Morris Management | 12/30/21 | $120,000 |
David Mallery Management | 12/30/21 | $240,000 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $1,000,000 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $1,000,000 |
| Total Program Service Revenue | $138 |
| Investment income | $44,540 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $1,410,815 |
| Net Gain/Loss on Asset Sales | $895,188 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $3,350,681 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $440,265 |
| Compensation of current officers, directors, key employees. | $440,265 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $0 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $11,498 |
| Fees for services: Accounting | $36,109 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $0 |
| Advertising and promotion | $0 |
| Office expenses | $5,613 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $1,380,085 |
| Travel | $5,084 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $5,960 |
| Insurance | $20,860 |
| All other expenses | $1,783 |
| Total functional expenses | $2,004,244 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $1,623,668 |
| Savings and temporary cash investments | $275,899 |
| Pledges and grants receivable | $1,000,000 |
| Accounts receivable, net | $115,568 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $130,594 |
| Net Land, buildings, and equipment | $22,553 |
| Investments—publicly traded securities | $9,926,609 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $776,846 |
| Total assets | $13,871,737 |
| Accounts payable and accrued expenses | $139,152 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $139,152 |
| Net assets without donor restrictions | $12,732,585 |
| Net assets with donor restrictions | $1,000,000 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $13,871,737 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Jonsson Cancer Center Foundation- Ucla Los Angeles, CA | $29,334,497 | $13,187,047 |
Translational Research In Oncology Us Inc Los Angeles, CA | $23,537,777 | $8,265,596 |
Pediatric Cancer Research Foundation Irvine, CA | $3,627,407 | $2,821,956 |
Nevada Cancer Research Foundation Inc Las Vegas, NV | $637,661 | $2,412,271 |
The International Genomics Consortium Phoenix, AZ | $13,871,737 | $3,350,681 |
Cancer Prevention Institute of California (CPIC) Foster City, CA | $0 | $44,595 |
Western States Cancer Research Ncorp Denver, CO | $1,626,947 | $1,539,378 |
Cancer League Of Colorado Inc Englewood, CO | $719,540 | $1,684,307 |
Vanguard Cancer Foundation Long Beach, CA | $1,374,337 | $177,388 |
Prostate Cancer Research Institute Culver City, CA | $2,240,081 | $999,786 |
Keatons Child Cancer Alliance Roseville, CA | $375,909 | $787,785 |
Ethos Discovery San Diego, CA | $1,024,175 | $920,855 |